PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTanezumab
Tanezumab
Tanezumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against beta-nerve growth factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N02: Analgesics
N02B: Other analgesics and antipyretics in atc
N02BG: Other analgesics and antipyretics in atc
N02BG12: Tanezumab
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoarthritisD010003EFO_0002506M15-M1941721
Knee osteoarthritisD020370EFO_0004616M173710
Low back painD017116HP_0003419M54.51337
Hip osteoarthritisD015207EFO_1000786M16156
ArthritisD001168HP_0001369M05-M14156
Back painD001416HP_0003418M54325
Neoplasm metastasisD009362EFO_0009708213
Cancer painD000072716G89.322
PainD010146EFO_0003843R52112
Chronic painD059350HP_001253211
Show 2 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spine osteoarthritisD055013EFO_100078711
Healthy volunteers/patients11
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTanezumab
INNtanezumab
Description
Tanezumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>4EDW:H|tanezumab Fab heavy chain QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSL KLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKTSHHHHHHG >4EDW:L|tanezumab Fab light chain DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQP EDIATYYCQQEHTLPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB4EDW
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108567
ChEBI ID
PubChem CID
DrugBankDB12335
UNII IDEQL0E9GCX1 (ChemIDplus, GSRS)
Target
Agency Approved
NGF
NGF
Organism
Homo sapiens
Gene name
NGF
Gene synonyms
NGFB
NCBI Gene ID
Protein name
beta-nerve growth factor
Protein synonyms
nerve growth factor (beta polypeptide), nerve growth factor, beta subunit, pro-nerve growth factor long
Uniprot ID
Mouse ortholog
Ngf (18049)
beta-nerve growth factor (Q6LDB7)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
89 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use